Skip to main content

Closed

BCAB: BioAtla, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-81.8% / yr

Operating margin-2525.0%

ROIC477.9%

Financially safe

Stretched

Debt / equity-0.16×

Interest coverage0.0×

Current ratio0.15×

BioAtla, Inc.

BCABNASDAQ Global Market·USD·Closed

BioAtla, Inc.

BCABNASDAQ·USD·Closed

$3.29

−2.66%

$3.29

−$0.09 (2.66%)

52W Range

0thpctl

Volume

0.26×avg

Mkt Cap

4.15MUSD

P/E

-0.1TTM

Div Yield

–ann

52W Range

0thpctl

Volume

0.26×avg

Market Cap

4.15MUSD

P/E Ratio

-0.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings